The GLP-1 boom has a dark side
The FDA has ordered new eye-risk warnings on a dozen GLP-1 drugs including Ozempic and Zepbound, escalating safety scrutiny of the blockbuster weight-loss class.
43 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 43 separate news trends connected to Wegovy, spanning June 18, 2026 through November 16, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 340 article observations and 325 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
The FDA has ordered new eye-risk warnings on a dozen GLP-1 drugs including Ozempic and Zepbound, escalating safety scrutiny of the blockbuster weight-loss class.
Novo Nordisk’s Q3 obesity‑drug surge lifts its 2026 outlook, putting investors front and centre.
Novo Nordisk’s Wegovy weight‑loss pill drives a sharp uplift in guidance, sparking a notable rally in its shares and market optimism.
Menopause hormone therapy may boost the weight‑loss power of GLP‑1 drugs, sparking interest from patients, doctors and pharma alike.
Novo's next-generation obesity drug surprises with 25% weight loss in women, despite demand concerns.
15% of Americans have taken a GLP-1, and dermatologists now have a timeline for when the hair goes.
US study links GLP-1 drugs to rare vision loss
Rare vision risk linked to GLP-1 drugs sparks concern
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
GLP-1s shift from 'patients' to 'customers' as weight loss trend surges
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
18 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Genetic link between GLP-1 receptor activation and better mental well‑being sparks new buzz in diabetes drugs
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
9 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Popular GLP-1 drugs linked to life-threatening brain disorder and suicidal thoughts after weight regain.
Weight loss drugs linked to fewer asthma attacks, study finds
Weight regain after obesity drugs spikes risk of suicidal thoughts, study finds
Novo’s child obesity win sparks hope, but simultaneous heart‑drug trial cuts cloud its broader pipeline.
A childhood‑obesity drug once reserved for adults now shows weight‑loss promise in kids as young as six.
Ozempic may boost mental health, sparking debate over GLP‑1 drugs' psychological impact
GLP-1 medications may worsen or speed hair loss in some men, study finds.
A surge in GLP‑1 prescriptions turns personal weight‑loss choices into a public debate demanding explanations.
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
GLP-1 medications, known for weight loss, are now being studied for their potential to treat addictions.
New research has linked a popular GLP medication to increased hair loss, sparking discussions among health experts.
New research suggests that popular weight-loss drugs may work differently than previously understood.
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Health regulators and legal firms are responding to a linked risk of rare blindness and eye disorders associated with GLP-1 weight-loss medications.
New economic research identifies a correlation between GLP-1 weight-loss drug usage and a 17% reduction in employee sick leave.
Reports and litigation are emerging over a potential link between GLP-1 weight loss medications and a rare, blinding eye condition.
Research suggests GLP-1 medications like Ozempic and Wegovy may provide a promising treatment for binge eating disorder.
Research is examining the weight-related consequences of discontinuing GLP-1 medications like Ozempic and Wegovy.
Rising concerns over GLP-1 weight-loss drug overdoses are linked to dosing errors and the use of telehealth services.
GLP-1 weight loss drugs are being used by a record number of Americans.
Wegovy has launched a daily oral pill for weight management in the UK, marking a shift from injectable treatments to pharmacy-available medication.
New study data suggests GLP-1 medications like Ozempic and Wegovy may reduce fracture risks and improve bone health in Type 2 diabetes patients.
New research indicates a trend of decreased physical activity among individuals using GLP-1 weight loss medications like Ozempic and Wegovy.